Theravance Biopharma (Theravance Biopharma) Price-to-Operating-Cash-Flow : (As of May. 02, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Price-to-Operating-Cash-Flow?

As of today (2024-05-02), Theravance Biopharma's share price is $8.84. Theravance Biopharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.46. Hence, Theravance Biopharma's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Theravance Biopharma's Price-to-Operating-Cash-Flow or its related term are showing as below:

TBPH's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 26.12
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Theravance Biopharma's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.02. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.46.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 50.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 23.00% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 11.60% per year.

During the past 12 years, Theravance Biopharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 50.50% per year. The lowest was -24.60% per year. And the median was 11.40% per year.

Theravance Biopharma Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Theravance Biopharma's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Price-to-Operating-Cash-Flow Chart

Theravance Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Theravance Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Theravance Biopharma's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Theravance Biopharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theravance Biopharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Price-to-Operating-Cash-Flow falls into.

Theravance Biopharma Price-to-Operating-Cash-Flow Calculation

Theravance Biopharma's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	8.84	/	-0.461
	=

Theravance Biopharma's Share Price of today is $8.84.
Theravance Biopharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Theravance Biopharma Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (Theravance Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (NAS:TBPH) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

0TB:Germany

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Executives

Rhonda Farnum	officer: SVP, Comm & Medical Affairs	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Richard A Graham	officer: SVP, Development	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kelly James Connor	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Brett A. Grimaud	officer: SVP, Gen Counsel and Secretary	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Aziz Sawaf	officer: SVP & Chief Financial Officer	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Rick E Winningham	director, officer: Chief Executive Officer	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Andrew A. Hindman	officer: SVP, Chief Financial Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Eli Samaha	10 percent owner	ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007
Wam Gp Llc	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Weiss Asset Management Lp	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Philip D Worboys	officer: SVP, Translational Science	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Brett K Haumann	officer: VP-Clinical Develop.	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402